Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Products under Development by Stage of Development | 7 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Products under Development by Therapy Area | 8 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Products under Development by Indication | 9 | 2 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Products under Development by Companies | 12 | 2 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Therapeutics Assessment | 14 | 5 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 19 | 3 |
| Arno Therapeutics, Inc. | 19 | 1 |
| Sunesis Pharmaceuticals, Inc. | 20 | 1 |
| Tolero Pharmaceuticals, Inc. | 21 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drug Profiles | 22 | 7 |
| AR-12 Drug Profile | 22 | 3 |
| HCI-1680 Drug Profile | 25 | 1 |
| HCI-1708 Drug Profile | 26 | 1 |
| PHT-427 Drug Profile | 27 | 1 |
| SNS-229 Drug Profile | 28 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Dormant Projects | 29 | 1 |
| 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Featured News &Press Releases | 30 | 10 |
| Nov 09, 2015: Sunesis Pharmaceuticals Presents Preclinical Data From Its PDK1 Inhibitor SNS-229 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 30 | 1 |
| Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis | 31 | 1 |
| Oct 27, 2015: Sunesis Pharmaceuticals Announces Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 31 | 1 |
| Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains | 32 | 1 |
| Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference | 33 | 1 |
| Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs | 33 | 2 |
| Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition | 35 | 1 |
| Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 | 35 | 1 |
| May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research | 36 | 1 |
| May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 | 37 | 1 |
| Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases | 38 | 1 |
| Aug 27, 2009: Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway | 38 | 1 |
| May 11, 2009: FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway | 39 | 1 |
| Appendix | 40 | 2 |
| Methodology | 40 | 1 |
| Coverage | 40 | 1 |
| Secondary Research | 40 | 1 |
| Primary Research | 40 | 1 |
| Expert Panel Validation | 40 | 1 |
| Contact Us | 40 | 1 |
| Disclaimer | 41 | 1 |
